As PD-L1 expression is upregulated in DOX-treated CRC cells, it would be important to counteract PD-L1 using a blockade of PD-1/PD-L1 in DOX-treated CRC cells and evaluate whether this would increase the drug efficiency. This evidence concerns the gene CD274 and colorectal carcinoma.